Keck School Faculty

Jacek K Pinski, MD, PhD
Jacek K Pinski, MD, PhD
Associate Professor of Medicine
Medicine
NOR 3446 Health Sciences Campus Los Angeles
After completing a fellowship at the Johns Hopkins Cancer Center in Baltimore, Dr. Pinski came to the Keck School of Medicine at USC as an Assistant Professor of Medicine. A former Research Assistant Professor at the Endocrine, Polypeptide and Cancer Institute at the Tulane University School of Medicine, Dr. Pinski is currently the Co-Director of the USC/Norris Comprehensive Cancer Center’s Prostate Cancer Research Center.

Dr. Pinski is also a member of the Rehabilitation Research and Development Section for the United States Department of Veteran Affairs. He has received funding for seven research studies and in 2006 was invited to lecture in Austraila at the 3rd Annual Pacific Rim Breast and Prostate Cancer Meeting. Dr. Pinski has had over 60 peer reviewed articles published and has given presentations all across the globe.

: Ooops. Something went wrong., 2002

: ACS/IRG Award, 2002

: Whitney Award, 2002

: Wright Award, 2002

: Stop Cancer Research Career Development Award, 2002

American Association for Cancer Research: Ooops. Something went wrong., 2001

Johns Hopkins University: Ooops. Something went wrong., 2001

Johns Hopkins University: Fellowship Research Award, 2001

GlaxoSmithKline: Ooops. Something went wrong., 2001

: Stop Cancer Award Special Seed Award, 2001

GlaxoSmithKline: Fellowship Award, 2001

American Association for Cancer Research: Translational Research Award, 2001

: Ooops. Something went wrong., 2001

A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers Clin Cancer Res. 2019 Jan 01; 25(1):43-51. . View in PubMed

A phase II trial of the aurora kinase A inhibitor alisertib for patients with castration resistant and neuroendocrine prostate cancer: efficacy and biomarkers Clin Cancer Res. 2018 Sep 19. . View in PubMed

Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types Biochem Biophys Res Commun. 2018 Jun 07; 500(3):621-625. . View in PubMed

Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types Biochem Biophys Res Commun. 2018 06 07; 500(3):621-625. . View in PubMed

A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer Clin Genitourin Cancer. 2017 Dec; 15(6):742-749. . View in PubMed

A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer Clin Genitourin Cancer. 2017 12; 15(6):742-749. . View in PubMed

Novel Gene Expression Signature Predictive of Clinical Recurrence After Radical Prostatectomy in Early Stage Prostate Cancer Patients Prostate. 2016 Oct; 76(14):1239-56. . View in PubMed

Novel Gene Expression Signature Predictive of Clinical Recurrence After Radical Prostatectomy in Early Stage Prostate Cancer Patients Prostate. 2016 10; 76(14):1239-56. . View in PubMed

Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile CancerClin Genitourin Cancer. 2016 10; 14(5):450-456. e1. . View in PubMed

Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era Can Urol Assoc J. 2016 Jan-Feb; 10(1-2):E17-22. . View in PubMed

Effects of luteinizing hormone receptor signaling in prostate cancer cells Prostate. 2015 Feb; 75(2):141-50. . View in PubMed

Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression PLoS One. 2015; 10(2):e0117758. . View in PubMed

Phase I, dose-escalation study of the targeted cytotoxic LHRH analog AEZS-108 in patients with castration- and taxane-resistant prostate cancer Clin Cancer Res. 2014 Dec 15; 20(24):6277-83. . View in PubMed

A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer Prostate Cancer Prostatic Dis. 2014 Dec; 17(4):359-65. . View in PubMed

Differential effects of RUNX2 on the androgen receptor in prostate cancer: synergistic stimulation of a gene set exemplified by SNAI2 and subsequent invasiveness Cancer Res. 2014 May 15; 74(10):2857-68. . View in PubMed

Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases Urology. 2014 Jan; 83(1):159-65. . View in PubMed

Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer Clin Genitourin Cancer. 2013 Dec; 11(4):416-22. . View in PubMed

Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer J Nucl Med. 2013 Aug; 54(8):1195-201. . View in PubMed

LHRH and LHR genotypes and prostate cancer incidence and survival Int J Mol Epidemiol Genet. 2013; 4(4):228-34. . View in PubMed

Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer Clin Nucl Med. 2012 Jul; 37(7):637-43. . View in PubMed

AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors Expert Opin Investig Drugs. 2012 Jun; 21(6):891-9. . View in PubMed

Immune response to sipuleucel-T in prostate cancer Cancers (Basel). 2012 Apr 18; 4(2):420-41. . View in PubMed

Ethnic differences in neuroendocrine expression in prostate cancer tissue Anticancer Res. 2011 Nov; 31(11):3897-901. . View in PubMed

Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer Maturitas. 2011 Aug; 69(4):296-303. . View in PubMed

Effect of luteinizing hormone on the steroidogenic pathway in prostate cancer Prostate. 2011 Jun 01; 71(8):892-8. . View in PubMed

Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer Expert Opin Investig Drugs. 2011 Jun; 20(6):769-78. . View in PubMed

Advanced prostate cancer: new agents, new questions Oncology (Williston Park). 2011 May; 25(6):509, 512. . View in PubMed

Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors Am J Clin Oncol. 2011 Feb; 34(1):27-31. . View in PubMed

Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors Curr Drug Deliv. 2011 Jan; 8(1):11-25. . View in PubMed

The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes Prostate. 2010 Nov 01; 70(15):1692-700. . View in PubMed

Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists Clin Cancer Res. 2010 Sep 15; 16(18):4675-80. . View in PubMed

The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo Prostate. 2010 Sep 01; 70(12):1359-70. . View in PubMed

Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer Clin Cancer Res. 2010 Jun 01; 16(11):3028-34. . View in PubMed

Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial Clin Genitourin Cancer. 2009 Jan; 7(1):43-50. . View in PubMed

Gene profiling and pathway analysis of neuroendocrine transdifferentiated prostate cancer cells Prostate. 2009 Jan 01; 69(1):12-23. . View in PubMed

A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer BJU Int. 2008 Dec; 102(11):1601-6. . View in PubMed

Both beta-actin and GAPDH are useful reference genes for normalization of quantitative RT-PCR in human FFPE tissue samples of prostate cancer Prostate. 2008 Oct 01; 68(14):1555-60. . View in PubMed

Prognostic value of the androgen receptor and its coactivators in patients with D1 prostate cancer Anticancer Res. 2008 Jan-Feb; 28(1B):425-30. . View in PubMed

Diet and prostate cancer risk reduction Expert Rev Anticancer Ther. 2008 Jan; 8(1):43-50. . View in PubMed

The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial Clin Genitourin Cancer. 2007 Dec; 5(7):433-7. . View in PubMed

Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival Hum Pathol. 2007 Oct; 38(10):1547-52. . View in PubMed

Evolving treatment paradigms for locally advanced and metastatic prostate cancer Expert Rev Anticancer Ther. 2006 Nov; 6(11):1639-51. . View in PubMed

Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells Mol Cell Biol. 2006 Oct; 26(19):7331-41. . View in PubMed

Genistein-induced neuroendocrine differentiation of prostate cancer cells Prostate. 2006 Aug 01; 66(11):1136-43. . View in PubMed

Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer Urology. 2006 Jun; 67(6):1247-52. . View in PubMed

Postchemotherapy residual masses in advanced seminoma: current management and outcomes Expert Rev Anticancer Ther. 2005 Oct; 5(5):869-74. . View in PubMed

Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines Mol Cancer Ther. 2005 Jul; 4(7):1105-13. . View in PubMed

EphB4 expression and biological significance in prostate cancer Cancer Res. 2005 Jun 01; 65(11):4623-32. . View in PubMed

Ethnic differences in neuroendocrine cell expression in normal human prostatic tissue Urology. 2005 May; 65(5):1008-12. . View in PubMed

Prostate cancer metastases to bone: pathophysiology, pain management, and the promise of targeted therapy Eur J Cancer. 2005 Apr; 41(6):932-40. . View in PubMed

Glucose metabolism of human prostate cancer mouse xenografts Mol Imaging. 2005 Apr-Jun; 4(2):91-7. . View in PubMed

Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results J Urol. 2004 Dec; 172(6 Pt 1):2252-5. . View in PubMed

Inhibitory effect of IL-6-induced neuroendocrine cells on prostate cancer cell proliferation Prostate. 2004 Nov 01; 61(3):253-9. . View in PubMed

Interleukin-6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation Int J Cancer. 2004 Sep 10; 111(4):508-13. . View in PubMed

A new screening system for proliferation-independent anti-cancer agents Cancer Lett. 2004 Jul 08; 210(1):119-24. . View in PubMed

Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma Clin Nephrol. 2003 Dec; 60(6):395-400. . View in PubMed

FDG PET in suspected recurrent and metastatic prostate cancer Oncol Rep. 2003 Sep-Oct; 10(5):1485-8. . View in PubMed

Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts Cancer Res. 2002 Feb 15; 62(4):986-9. . View in PubMed

Powered by SC CTSI
Go to Top